Primary Outcome Measures Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), changes in laboratory values, vital signs and electrocardiogram (ECG) [ Time Frame: Cycle 1 Day 1 to 30 days after the last dose of HFB200301 (each cycle is 28 days), assessed up to 3 years ] To determine[…]
Full Archive
The immunotherapy Drug Bevacizumab Can Improve Survival in Mesothelioma Patients
An immune system boosting therapy could potentially be used to treat mesothelioma. For a long period of time, chemotherapy drugs have been the standard drug to fight mesothelioma, but researchers believe bevacizumab could change this and be used alongside standard mesothelioma treatments. Chemotherapy is popular with doctors, but chemotherapy drugs[…]
Researchers are Studying the Mesothelioma Tumor Microenvironment
A new study is showing how the tumor microenvironment helps mesothelioma progress and survive in the body. Mesothelioma tumors create a complex microenvironment surrounding themselves. The microenvironment is simply the area surrounding the tumors. The new study shows that the microenvironment that mesothelioma tumors create assists cancer initiation and progression.[…]
Different Levels of Pleurectomy and Decortication Surgery can Save Mesothelioma Patients’ Lives
Italian researchers believe that lung sparing surgery can improve survival in mesothelioma patients, even when surgeries are more conservative. Pleurectomy and decortication is the surgery that spares the lungs. It is less comprehensive than the surgery that removes the lungs, which also makes it less dangerous to patients. Doctors at[…]
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Primary Outcome Measures Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 21 Days ] A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by[…]
ERAS® Guidelines Validation of CRS With or Without HIPEC
Primary Outcome Measures Compliance of ERAS® guidelines [ Time Frame: 3 months ] Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines Secondary Outcome Measures Acceptance and feasibility of ERAS® guidelines [ Time Frame: 3 months ] Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines Inclusion Criteria Adults female and[…]
A Virus that Affects Goats Could Help Treat Mesothelioma
Mesothelioma, a cancer of the membrane that surrounds the lungs, abdomen, heart, and testicles is a very aggressive cancer. It spreads very quickly and when the tumors grow big enough, they crowd out organs and make it hard for people to breath. Mesothelioma sufferers can experience coughing, chest pain, and[…]
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Primary Outcome Measures ORR [ Time Frame: 6 months after the final enrollment ] Objective Response Rate（ORR）according to mRECIST 1.1 standard Secondary Outcome Measures DOR [ Time Frame: 24 months ] Duration of remission DCR [ Time Frame: 24 months ] Disease Control Rate PFS [ Time Frame: 24 months ] Progression Free Survival OS [ Time Frame: 24 months ] Overall Survival AE [ Time Frame: 24 months ] Adverse event SAE [ Time Frame: 24[…]
Epigenetics Used to Improve Immunotherapy for Mesothelioma
Researchers are looking into changing mesothelioma cells to make them more susceptible to immunotherapy. Mesothelioma is a hard cancer to treat, so new approaches need to be developed to try to lengthen and improve mesothelioma patients’ lives. Immunotherapy can work well for some, but for others it does very little,[…]
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Primary Outcome Measures Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma [ Time Frame: 3 months to 4 years ] Assessment by the review of pathologists Inclusion Criteria peritoneal malignant mesothelioma Exclusion Criteria opposition to reuse personnal data
